475111-38-7

Basic information

• Product Name: 4-(4-CHLORO-6-(2-(DIFLUOROMETHYL)-1H-BENZO[D]IMIDAZOL-1-YL)-1,3,5-TRIAZIN-2-YL)MORPHOLINE
• Synonyms: 1-[4-chloro-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-2-(difluoromethyl)-1H-Benzimidazole;1-[4-chloro-6-(Morpholin-4-yl)-1,3,5-triazin-2-yl]-2-(difluoroMethyl)-1H-1,3-benzodiazole;1-(4-chloro-6-Morpholino-1,3,5-triazin-2-yl)-2-(difluoroMethyl)-1H-benzo[d]iMidazole;-1,3,5-triazin-2-yl);-1H-benzo[d]imidazol-1-yl);4-(4-Chloro-6-(2-(difluoromethyl);4-(4-CHLORO-6-(2-(DIFLUOROMETHYL)-1H-BENZO[D]IMIDAZOL-1-YL)-1,3,5-TRIAZIN-2-YL)MORPHOLINE;EOS-60790
• CAS NO: 475111-38-7
• Molecular Formula: C₁₅H₁₃ClF₂N₆O
• Molecular Weight: 366.75
• Mol File: 475111-38-7.mol
• Article Data: 15

Chemical Properties

• Melting Point: 230-231 °C(Solv: ethanol (64-17-5))
• Boiling Point: 583.038 °C at 760 mmHg
• Flash Point: 306.411 °C
• Appearance: /
• Density: 1.652 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.716
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 1.53±0.10(Predicted)
• CAS DataBase Reference: 4-(4-CHLORO-6-(2-(DIFLUOROMETHYL)-1H-BENZO[D]IMIDAZOL-1-YL)-1,3,5-TRIAZIN-2-YL)MORPHOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-CHLORO-6-(2-(DIFLUOROMETHYL)-1H-BENZO[D]IMIDAZOL-1-YL)-1,3,5-TRIAZIN-2-YL)MORPHOLINE(475111-38-7)
• EPA Substance Registry System: 4-(4-CHLORO-6-(2-(DIFLUOROMETHYL)-1H-BENZO[D]IMIDAZOL-1-YL)-1,3,5-TRIAZIN-2-YL)MORPHOLINE(475111-38-7)

Safety Data

• Hazardous Substances Data: 475111-38-7(Hazardous Substances Data)

Usage

General Description

4-(4-Chloro-6-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-1,3,5-triazin-2-yl)morpholine is a chemical compound that belongs to the class of morpholine derivatives. It contains a morpholine ring attached to a 1,3,5-triazine ring, which in turn is attached to a benzo[d]imidazole group. Additionally, the 1,3,5-triazine ring has a difluoromethyl group and a chloro group attached to it. 4-(4-CHLORO-6-(2-(DIFLUOROMETHYL)-1H-BENZO[D]IMIDAZOL-1-YL)-1,3,5-TRIAZIN-2-YL)MORPHOLINE may have potential pharmaceutical applications given its unique structure and the presence of heterocyclic rings, which are commonly found in bioactive molecules. Further research can be conducted to explore its biological activities and potential therapeutic uses.

InChI:InChI=1/C15H13ClF2N6O/c16-13-20-14(23-5-7-25-8-6-23)22-15(21-13)24-10-4-2-1-3-9(10)19-12(24)11(17)18/h1-4,11H,5-8H2

Upstream product

• 95-54-5 1,2-diamino-benzene 
• 3764-01-0 2,4,6-trichloropyrimidine 
• 6601-22-5 2,6-Dichloro-4-morpholino-1,3,5-triazine 
• 705-09-9 2-(difluoromethyl)-1H-benzo[d]imidazole 

Downstream Products

• 1401512-31-9 N-(1-benzylcyclopropyl)-4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-amine 
• 1401512-33-1 N-(1-benzylcyclopentyl)-4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-amine 
• 1401512-28-4 4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-N-(1-phenylcyclopropyl)-1,3,5-triazin-2-amine 
• 1401512-37-5 4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-N-(1-benzylcyclobutyl)-6-morpholino-1,3,5-triazin-2-amine 
• 1401512-32-0 N-(1-(4-bromobenzyl)cyclohexyl)-4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-amine 
• 1401512-34-2 4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-N-(1-(2-methylbenzyl)cyclopropyl)-6-morpholino-1,3,5-triazin-2-amine 
• 1416956-33-6 (S)-2-amino-1-(4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)piperazin-1-yl)-3-phenylpropan-1-one 
• 1416956-15-4 (S)-tert-butyl (1-(4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)piperazin-1-yl)-1-oxo-3-phenylpropan-2-yl)carbamate 
• 1416956-34-7 (R)-2-amino-1-(4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)piperazin-1-yl)-3-phenylpropan-1-one 
• 1416956-36-9 (S)-2-amino-1-(4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-yl)-6-morpholino-1,3,5-triazin-2-yl)piperazin-1-yl)-3-(4-hydroxyphenyl)propan-1-one 
• 1416956-16-5 (R)-tert-butyl (1-(4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)piperazin-1-yl)-1-oxo-3-phenylpropan-2-yl)carbamate 
• 1416956-20-1 (S)-tert-butyl (1-(4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)piperazin-1-yl)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)carbamate 
• 1359963-04-4 1-[4-({4-[2-(difluoromethyl)-1H-benzimidazol-1-yl]-6-(morpholin-4-yl)-1,3,5-triazin-2-yl}oxy)phenyl]ethanone 
• 1401436-63-2 N-(1-(2-bromophenyl)-2-methylpropan-2-yl)-4-(2-(difluoromethyl)-1H-benzo[d]imidazole-1-yl)-6-morpholino-1,3,5-triazin-2-amine 

Relevant articles and documents

Discovery of novel PARP/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer

Co-targeting PARP and PI3K by PARP/PI3K dual inhibitors has been recognized as a promising chemotherapeutic strategy for the treatment of triple negative breast cancer (TNBC) in our previous work. To further explore novel and more potent PARP/PI3K dual in

PARP-1 and PI3K double-target inhibitor containing benzofuran

The invention relates to the field of medicinal chemistry, in particular to a PARP-1 and PI3K double-target inhibitor containing a benzofuran structure (I) (the formula I is shown in the description),a preparation method and a medicine composition containing thereof. Proved by a pharmacodynamic test, the PARP-1 and PI3K double-target inhibitor has the anti-tumor effect.

NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF

The present invention describes heterocyclic compounds of general Formula 1 and their method of preparation thereof. The present invention describes general Formula 1 which inhibits phosphoinositide 3-kinase (PI3K) and can be used as the anticancer agents